LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akcijų sąrašas・Organon & Co

Search

Organon & Co

Uždarymo kaina

SektoriusSveikatos priežiūra

13.4 -0.22

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.39

Max

13.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	351M 146M
Pardavimai	-47M 1.5B
P/E Sektoriaus vid.	14.441 50.102
Pelnas, tenkantis vienai akcijai	0.71
Dividendų pajamingumas	0.6
Pelno marža	10
Darbuotojai	10,000
EBITDA	286M 351M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-8.19% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.60% 2.33%
Kitas uždarbis	2026-08-04
Kitas dividendų mokėjimo data	2026-06-11
Kita Ex Dividend data	2026-08-14

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	71M 3.5B
Ankstesnė atidarymo kaina	13.62
Ankstesnė uždarymo kaina	13.4

Naujienos nuotaikos

By Acuity

74%

26%

306 / 344 reitingas Healthcare

Organon & Co Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 06:09; UTC

Įsigijimai, susijungimai, perėmimai

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

2026-04-27 02:33; UTC

Įsigijimai, susijungimai, perėmimai

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

2026-04-27 01:04; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

2025-11-07 14:41; UTC

Įsigijimai, susijungimai, perėmimai

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

2026-04-27 18:07; UTC

Įsigijimai, susijungimai, perėmimai

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

2026-04-27 15:14; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

2026-04-27 14:56; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

2026-04-27 13:58; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

2026-04-27 13:38; UTC

Karštos akcijos

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

2026-04-27 12:18; UTC

Įsigijimai, susijungimai, perėmimai

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

2026-04-27 09:22; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

2026-04-27 00:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

2026-04-27 00:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 17:09; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 14:39; UTC

Įsigijimai, susijungimai, perėmimai

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 14:01; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 09:23; UTC

Karštos akcijos

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Akcijų palyginimas

Kainos pokytis

Organon & Co Prognozė

Kainos tikslas

By TipRanks

-8.19% į apačią

12 mėnesių prognozė

Vidutinis 12.33 USD -8.19%

Aukščiausias 14 USD

Žemiausias 9 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Organon & Co kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

0

Pirkti

4

Laikyti

0

Parduoti

Remiantis 4 analitikų, pateikusių Organon & Co akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

306 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

1,066.57

JNJ

Johnson and Johnson

230.23

ABBV

AbbVie Inc

212.63

UNH

UnitedHealth Group Inc

377.52

AZN

AstraZeneca PLC

187.14

Live chat